What is this study trying to find out about hepatocellular carcinoma?

This study aims to find out if liver and spleen stiffness measurements using elastography are linked to the risk of hepatocellular carcinoma returning after radiofrequency ablation treatment. It also looks at how these measurements relate to survival and liver health. The study is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who may be eligible for this hepatocellular carcinoma clinical trial?

Adults aged 18 or older with chronic liver disease who are candidates for radiofrequency ablation treatment for hepatocellular carcinoma may be eligible. The study includes all genders but excludes those with recent liver transplant or surgery, severe liver decompensation, or other serious diseases. Please review eligibility criteria for more details.

Is there any cost to participate in this hepatocellular carcinoma clinical trial?

Study-related care, including any procedures and trial visits, is provided at no cost. However, personal travel and other expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Age: 18Years +

All Genders

ID06777017

Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-15

Participants Needed

Research Sites

30 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the relationship between liver and spleen stiffness, measured by elastography, and the risk of hepatocellular carcinoma (HCC) coming back after treatment with radiofrequency ablation (RFA). This observational study also aims to explore whether these elastography values relate to overall survival, HCC-related survival, and risk of liver decompensation. Additionally, the study will assess connections between non-invasive biochemical tests and HCC recurrence risk in patients with chronic liver disease undergoing RFA. Participants are patients with chronic liver disease diagnosed with HCC who are candidates for RFA treatment. The study involves performing hepatic or splenic elastography using transient elastography (Fibroscan®) or Acoustic Radiation Force Impulse (ARFI) methods. Participants will be followed to observe the association of these elastography measurements with clinical outcomes after RFA treatment. During the study, participants will undergo elastography procedures to measure liver and spleen stiffness and provide biochemical test samples. The main outcome measured is the association between elastography values and HCC recurrence risk over 12 months following RFA. Researchers will also monitor overall and HCC-related survival and liver function status. The study is observational, with no additional interventions beyond routine care, and participation involves regular assessments and follow-up over the study period.